Nan Fung Life Sciences
San Francisco, California, United StatesFounded 2017
Nan Fung Life Sciences is a global investment platform that focuses on the life sciences industry, making direct investments through its Pivotal bioVenture Partners funds in the US and China, and also engaging in fund investments. Its strategy covers the full spectrum of the industry, including therapeutics, medical devices, and diagnostics, across various development stages, with a primary focus on Series B rounds in US-based startups and a significant presence in Greater China.
56% of their portfolio is in Healthcare. Average disclosed round size is $99.2M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
$1.5B
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ablaze Pharmaceuticals | Series A | $75M | Nov 2021 |
 Arctic Vision | Series B | $100M | Mar 2021 |
 Encodia | Series C | $75M | Jan 2021 |
 Omniome, Inc. | Series C | $60M | Jan 2020 |
 Oncologie | Series B | $80M | Jun 2019 |
 Eargo | Series D | $52M | Mar 2019 |
| SSomaLogic | Growth | $200M | Jan 2018 |
| Eargo | Unknown | $180M | — |
| Eargo | Series E | $71M | — |
Top Co-Investors
NEA (New Enterprise Associates)3 shared
Maveron2 shared
ARCH Venture Partners2 shared
Biomatics Capital2 shared
venBio1 shared
Samsara BioCapital1 shared
Advantech Capital1 shared
Korea Investment Partners1 shared
Longitude Capital1 shared
Future Fund1 shared
Tencent Investment1 shared
New World Development1 shared
Morningside Ventures1 shared
Domain Associates1 shared
Altitude Life Science Ventures1 shared
Northpond Ventures1 shared
Deerfield1 shared
GV (Google Ventures)1 shared
Alexandria Venture Investments1 shared
Tao Capital Partners1 shared
Last updated: 28 April 2026